Across TCGA pan-cancer cohorts, CELA2B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CELA2B data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CELA2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CELA2B expression acts as an unfavorable survival marker.

PDAC are the cancer types where CELA2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.540	0.951	.017	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: CELA2B tumor-vs-normal RNA expression · all CELA2B data types